Exposing the molecular heterogeneity of glycosylated biotherapeutics

Luis F. Schachner, Christopher Mullen, Wilson Phung, Joshua D. Hinkle, Michelle Irwin Beardsley, Tracy Bentley, Peter Day, Christina Tsai, Siddharth Sukumaran, Tomasz Baginski, Danielle DiCara, Nicholas J. Agard, Matthieu Masureel, Joshua Gober, Adel M. ElSohly, Rafael Melani, John E. P. Syka, Romain Huguet, Michael T. Marty and Wendy Sandoval ()
Additional contact information
Luis F. Schachner: Inc.
Christopher Mullen: Inc.
Wilson Phung: Inc.
Joshua D. Hinkle: Inc.
Michelle Irwin Beardsley: Inc.
Tracy Bentley: Inc.
Peter Day: Inc.
Christina Tsai: Inc.
Siddharth Sukumaran: Inc.
Tomasz Baginski: Inc.
Danielle DiCara: Inc.
Nicholas J. Agard: Inc.
Matthieu Masureel: Inc.
Joshua Gober: Inc.
Adel M. ElSohly: Inc.
Rafael Melani: Inc.
John E. P. Syka: Inc.
Romain Huguet: Inc.
Michael T. Marty: University of Arizona
Wendy Sandoval: Inc.

Nature Communications, 2024, vol. 15, issue 1, 1-13

Abstract: Abstract The heterogeneity inherent in today’s biotherapeutics, especially as a result of heavy glycosylation, can affect a molecule’s safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins or other heterogeneous biotherapeutics. Here, we present an approach to the molecular assessment of biotherapeutics that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact heterogeneous and/or glycosylated proteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment. For glycoproteins in particular, the method may offer insights into glycan composition when coupled with a suitable bioinformatic strategy. We tested the approach on various biotherapeutic molecules, including Fc-fusion, VHH-fusion, and peptide-bound MHC class II complexes to demonstrate efficacy in measuring the proteoform-level diversity of biotherapeutics. Notably, we inferred the glycoform distribution for hundreds of molecular weights for the eight-times glycosylated fusion drug IL22-Fc, enabling correlations between glycoform sub-populations and the drug’s pharmacological properties. Our method is broadly applicable and provides a powerful tool to assess the molecular heterogeneity of emerging biotherapeutics.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-47693-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47693-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-47693-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().